Want to see FR:ALIKO full AI Analyst Report?
Top Page
Ikonisys SA
(ALIKO)
Select Model
Select Model
Rating:46Neutral
Price Target:
€1.50
▲(2.74% Upside)
Action:Reiterated
Date:08/17/26
The score is primarily constrained by weak financial performance—persistent, sizable losses and ongoing cash burn—despite strong recent revenue growth and a comparatively healthier balance sheet. Technicals add further pressure as the stock trades below major moving averages with negative MACD, while valuation is also penalized because profitability is negative and there is no dividend support.
Positive Factors
Strong Revenue Growth
The sharp revenue acceleration indicates improving customer adoption and commercial traction. Sustained growth could expand the installed base and increase future consumables and service revenue, supporting a more scalable recurring-revenue model.
Negative Factors
Large Persistent Losses
Revenue growth has not yet translated into operating leverage. Very large, widening losses indicate that fixed costs, development spending, or commercialization expenses remain disproportionate to sales, limiting the credibility of near-term profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Growth
The sharp revenue acceleration indicates improving customer adoption and commercial traction. Sustained growth could expand the installed base and increase future consumables and service revenue, supporting a more scalable recurring-revenue model.
Read all positive factors
Ikonisys SA (ALIKO) vs. iShares MSCI France ETF (EWQ)
Market Cap
€22.42M
Dividend YieldN/A
Average Volume (3M)2.31K
Price to Earnings (P/E)―
Beta (1Y)0.23
Revenue Growth37.28%
EPS Growth7.83%
CountryFR
Employees15
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.29
Shares Outstanding15,843,148
10 Day Avg. Volume3,968
30 Day Avg. Volume2,309
Financial Highlights & Ratios
PEG Ratio-1.55
Price to Book (P/B)1.16
Price to Sales (P/S)16.02
P/FCF Ratio-19.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.09
Revenue Forecast (FY)€6.90M
Ikonisys SA Business Overview & Revenue Model
Company Description
Based in Paris, France, Ikonisys S.A. is a company specializing in cell-based diagnostics. It develops, produces, and commercializes medical diagnostic solutions for various cancers across the United States and Europe. Their core offering includes...
How the Company Makes Money
Ikonisys SA primarily makes money by selling (1) its diagnostic/cytogenetics instrumentation platforms (automated imaging and analysis systems) and (2) recurring consumables and related products used with those platforms (e.g., assay/reagent kits ...
Ikonisys SA Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
63
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.01M | 1.39M | 1.01M | 448.56K | 935.22K | 365.14K |
| Gross Profit | 715.37K | 897.27K | 715.37K | 255.83K | 751.80K | 28.46K |
| EBITDA | -1.70M | -1.28M | -1.70M | -927.41K | -1.35M | -483.65K |
| Net Income | -3.24M | -4.20M | -3.24M | -2.27M | -2.45M | -571.27K |
Balance Sheet | ||||||
| Total Assets | 27.40M | 26.71M | 27.40M | 20.85M | 21.72M | 22.52M |
| Cash, Cash Equivalents and Short-Term Investments | 25.08K | 1.03M | 25.08K | 9.40K | 93.98K | 1.52M |
| Total Debt | 4.13M | 3.25M | 4.13M | 3.40M | 2.51M | 1.24M |
| Total Liabilities | 13.14M | 7.58M | 13.14M | 5.12M | 4.04M | 2.50M |
| Stockholders Equity | 14.25M | 19.13M | 14.25M | 15.73M | 17.67M | 20.01M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -1.17M | -1.37M | -1.46M | -2.01M | -1.36M |
| Operating Cash Flow | 0.00 | -1.16M | -1.33M | -914.22K | -1.14M | -781.42K |
| Investing Cash Flow | 0.00 | -301.62K | -67.58K | -545.24K | -884.20K | -636.56K |
| Financing Cash Flow | 0.00 | 2.36M | 1.41M | 1.37M | 599.13K | 2.90M |
Ikonisys SA Technical Analysis
Negative
1.46
Price Trends
1.48
Negative
1.48
Negative
1.51
Negative
Market Momentum
-0.01
Positive
43.88
Neutral
11.11
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALIKO, the sentiment is Negative. The current price of 1.46 is above the 20-day moving average (MA) of 1.46, below the 50-day MA of 1.48, and below the 200-day MA of 1.51, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 43.88 is Neutral, neither overbought nor oversold. The STOCH value of 11.11 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALIKO.
Ikonisys SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | €35.71M | -0.96 | -96.46% | ― | 0.87% | 46.31% | |
54 Neutral | €196.11M | 41.49 | 2.71% | ― | 9.08% | 21.19% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | €30.85M | 7.68 | -58.93% | ― | 7.43% | ― | |
46 Neutral | €22.42M | -5.13 | -22.03% | ― | 37.28% | 7.83% | |
46 Neutral | €199.96M | -3.52 | 90.10% | ― | 1.79% | 15.89% |
* Healthcare Sector Average
FR:ALIKO
Ikonisys SA
1.40
-0.12
-7.89%
FR:ALMKT
MAUNA KEA TECHNOLOGIES
0.16
0.05
50.00%
FR:ALNOV
Novacyt
0.51
0.03
6.47%
FR:ALERS
Eurobio-Scientific SA
19.50
-5.75
-22.77%
FR:ALDMS
Diagnostic Medical Systems
1.02
-0.32
-23.97%
FR:ALMDT
Median Technologies
4.05
0.53
15.06%
Ikonisys SA Corporate Events
Aliko Scientific signs Romanian and Saudi distribution deals to boost cancer diagnostics reach
Aug 5, 2026
Aliko Scientific has expanded its international footprint in cancer diagnostics by signing distribution agreements in Romania with Proton Impex 2000 and in Saudi Arabia with H-Care Medical Est., covering its portfolio in liquid-based cytology, FIS...
Aliko Scientific boosts revenue and advances integrated oncology platform despite wider net loss
Jul 30, 2026
Aliko Scientific reported a 52.6% rise in total revenue to €1.64 million for 2025, driven by the full-year consolidation of Hospitex and the rollout of its integrated oncology diagnostics offering. EBITDA loss narrowed by about a third to &#...
Aliko Scientific Subsidiary Hospitex to Study National Urine24 Cancer Screening in Uzbekistan
Jul 23, 2026
Aliko Scientific’s subsidiary Hospitex International has signed an agreement with the Jizzakh branch of Uzbekistan’s Republican Scientific and Practical Centre for oncology and radiology to develop a feasibility study for a national ur...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.